Morgan Stanley Call 20 FOLD 20.09.../ DE000ME65UH8 /
| 2024-05-28 9:15:42 PM | Chg.+0.040 | Bid2024-05-28 | Ask2024-05-28 | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.200EUR | +25.00% | 0.200 Bid Size: 12,500 |
0.248 Ask Size: 12,500 |
Amicus Therapeutics ... | 20.00 USD | 2024-09-20 | Call |
GlobeNewswire
05-09
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
GlobeNewswire
05-08
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
GlobeNewswire
05-01
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
GlobeNewswire
03-20
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
GlobeNewswire
02-28
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
GlobeNewswire
02-15
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
GlobeNewswire
02-08
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga)...
GlobeNewswire
02-01
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
GlobeNewswire
01-07
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
GlobeNewswire
01-03
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
2023-12-05
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next Presiden...
GlobeNewswire
2023-11-08
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
GlobeNewswire
2023-11-01
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
GlobeNewswire
2023-10-27
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
GlobeNewswire
2023-10-03
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
GlobeNewswire
2023-10-02
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
GlobeNewswire
2023-09-28
Muscular Dystrophy Association Celebrates FDA Approval of Amicus Therapeutics’ Pombiliti + Opfolda f...
GlobeNewswire
2023-09-28
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
GlobeNewswire
2023-09-21
Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice Preside...
GlobeNewswire
2023-09-14
Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daph...
GlobeNewswire
2023-09-01
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
GlobeNewswire
2023-08-29
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
GlobeNewswire
2023-08-15
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
